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Objective. Biomaterial research for soft tissue augmentation is an increasing topic in aesthetic medicine. Hyaluronic acid (HA)
fillers are widely used for their low invasiveness and easy application to correct aesthetic defects or traumatic injuries. Some
complications as acute or chronic inflammation can occur in patients following the injection. Biocompatibility assays are
required for medical devices intended for human use, in order to prevent damages or injuries in the host. In this study, nine HA
fillers were tested in order to evaluate their cytotoxicity and their effects on L929 cell line, according to the UNI EN ISO 10993
regulation. Methods. Extracts were prepared from nine HA fillers, and MTS viability assay was performed after 24 h, 48 h, and
72 h of exposure of cells to extracts. Cells cultured with HA filler extracts were monitored for up to 72 h, counted, and stained
with haematoxylin/eosin in order to evaluate the cell proliferation rate and morphology. Results. None of the filler tested showed
a cytotoxic effect. Two samples showed a higher vitality percentage and higher cell number while two samples showed a lower
vitality percentage and lower cell number at 72 h. Conclusion. Data obtained suggest that although examined fillers are not
cytotoxic, they show different effects on the in vitro cell proliferation rate. In vitro studies of medical devices could lead to
important implications since these could aid to predict effects about their in vivo application. These easy and rapid assays could
be useful to test new materials intended for human use avoiding animal tests.
1. Introduction
In the last few years, biomaterial research for soft tissue aug-
mentation has been implemented for its application for the
correction of serious and slight aesthetic defects or traumatic
injuries [1]. Injectable fillers are widely used for their low
invasiveness and easy application. Fillers, as medical devices,
must be biocompatible by inducing an appropriate biological
response in a specific application, without causing damage or
injury [2]. This involve an interaction between the host envi-
ronment, the material, and the function that it must perform.
Biocompatibility is a dynamic process aimed at minimizing
any adverse reaction or rejection by the host [3]. Since a filler
integrates with the body, skin, and derma, the interaction of
the material with the surrounding tissues could be responsi-
ble of many biological reactions. Based on their chemical
composition, they can be classified into “biological fillers”
and “synthetic fillers”. The first ones consist on natural mol-
ecules that undergo skin resorption after a certain period of
time. They are represented by collagen, hyaluronic acid,
and polylactic acid. The “synthetic fillers” are derived from
synthesis processes, and their effect is more prolonged com-
pared to biological fillers. The most common synthetic fillers
are polyacrylamide, polymethylmethacrylate, polytetraethy-
lene, and povidone. Therefore, according to their longevity,
fillers can be permanent or temporary. The main advantage
from the use of fillers is obtaining harmonious and natural
results immediately, without resorting to invasive surgical
procedures. However, acute inflammatory reactions are the
most frequent complications that occur immediately follow-
ing the injection. Other complications are granulomas, her-
pes labialis, permanent redness, small necrosis, or abscesses.
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Chronic inflammations could occur after a certain period
[4, 5]. Hyaluronic acid (HA) is one of the most common
naturally derived filler, and, nowadays the most frequently
used, even if its short persistence, possible allergenicity, and
immunogenicity leads to the research of new synthetic
materials [5]. HA is an anionic, nonsulphated glycosami-
noglycan widely represented in connective, epithelial, and
neural tissues. HA is one of the major components of
the skin, and it is involved in tissue regeneration, due to
its high water-binding properties, maintaining proper tis-
sue volume. Impair of HA promotes biological ageing
and wrinkle development. A variety of HA-based fillers
has been approved for the treatment of wrinkles, scars,
and facial contouring defects [6]. HA used to produce
fillers is synthesized in laboratory from bacterial cultures.
In order to guarantee an adequate permanence once
injected into the tissues, HA chains undergo a cross-
linking process with linking substances, which ensure a
greater resistance to the action of enzymes in the body. One
of the most used linking substances is BDDE (1,4-butanediol
diglycidyl ether) [5].
HA dermal fillers are classified into two categories,
monophasic or biphasic. The monophasic ones consist of
solid particles of material, plunged in a fluid carrier sub-
stance, and appear as a homogeneous gel. Biphasic fillers
are composed of cross-linked HA particles immersed in a
fluid matrix consisting of low or zero cross-linked HA.
Monophasic HA fillers are more cohesive, may last longer,
and show a low migration rate after injection; biphasic HA
fillers are more easily customized and adaptable to the ana-
tomical area being treated [7].
A filler must be similar to the native tissue, durable, easily
implantable, and painless for the patient. Moreover, it should
be nontoxic, noncarcinogenic, inert, nonallergic, nonimmu-
nogenic, nonpyrogenic, and nonmigrating [2]. For this rea-
son, marketing of any device, intended for human use,
requires the assessment of the biological response [8]. The
evaluation of cytotoxicity is a crucial step to establish the bio-
compatibility of a material [9, 10]. The European Directive
63/2010/EU, defines the concept of 3Rs (Replacement, Reduc-
tion and Refinement) addressing the interest of the scientific
community towards the application of in vitro methods as
alternatives approach to the in vivo methods [11]. The inter-
action of cell cultures with potential toxic compounds
released by a biomaterial induces a detectable biological
response through which it is possible to establish the safety
of a material under examination. Cytotoxicity tests allow to
highlight the possible alterations in basic cellular functions
through the analysis of cellular metabolism, morphology,
and the proliferation rate or vitality [12]. The UNI EN ISO
10993/2009 rule, part five, describes suitable in vitromethods
to perform the biological evaluation of medical devices [13].
Tests can be performed through a direct or indirect contact
of cells with the material or through a contact with an extract,
depending on the nature and the shape of the material under
examination. [14–16]. Medical devices, including fillers for
aesthetic medicine, are not subject to any prior authorization
from the Competent Authority (Ministry of Health), as there
is a European regulation of “new approach”, according to
which medical devices are certified by notified bodies autho-
rized in the European Country [17].
This study is aimed at evaluating the biocompatibility of
nine commercially available different HA fillers by perform-
ing a cytotoxicity test and cell proliferation test on the L929
cell line.
2. Materials and Methods
2.1. Samples. Samples used were nine different HA fillers
commercially available with an average content of 20mg/ml
HA. Filler samples arrived in the laboratory sealed in their
packaging, and sterility was guaranteed by the manufacturer.
More detailed characteristics of each filler are described in
Table 1.
2.2. Cell Culture. L929 cell line (murine fibroblast) was
purchased from Cell Bank of National Reference Institute
for Alternative Methods, Welfare and Care of Laboratory
Animals (Istituto Zooprofilattico Sperimentale della Lombardia
ed Emilia Romagna, Italy). Cells were grown in culture flasks
containing minimum essential medium (MEM, Sigma-
Aldrich), supplemented with 10% fetal bovine serum (FBS,
Euroclone), 1% antibiotic-antimycotic solution (Sigma-
Aldrich), and 1% nonessential amino acids (NEAA, Euroclone).
Cells were maintained at +37°C in a humidified 5% CO2
atmosphere and monitored daily by using an inverted micro-
scope. Subcultures were performed twice a week, when an
80% of confluence was observed.
2.3. Sample Preparation. The “extraction dilution method”
was chosen as described by the UNI EN ISO 10993 regulation
[13]. Extraction procedure was carried out in an extraction
Table 1: Characteristics of the nine HA fillers used.
Samples Description
Filler 1
Stabilized hyaluronic acid 20mg/ml, nonanimal
origin, pH 6–7.5 biphasic
Filler 2
Cross-linked hyaluronic acid 20mg/ml with lidocaine
hydrochloride 3mg/ml, biphasic
Filler 3
Hyaluronic biorevitalizing gel, medium-chain
hyaluronic acid 20mg/ml in a physiologic buffer,
produced from Streptococcus equi bacteria
Filler 4
Hyaluronic acid 20mg/ml-sodium chloride
16mg/ml, from bacterial biofermentation, BDDE
cross-linking agent, monophasic
Filler 5
Reticulated hyaluronic acid 25mg/ml with lidocaine
hydrochloride 3mg/ml, animal origin, pH 7.2
Filler 6
Reticulated hyaluronic acid 24mg/ml in physiological
buffered saline, from biotechnological fermentation,
low BDDE content, monophasic
Filler 7
Auto cross-linked hyaluronic acid–sodium chloride
18mg/ml
Filler 8
Hyaluronic acid 2mg and cross-linked HA 20mg-
sodium chloride 6.9mg, nonanimal origin,
endotoxin- and BDDE-free
Filler 9
Cross-linked hyaluronic acid 20mg/ml-lidocaine
hydrochloride 3mg/ml pH 7, biphasic
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medium consisting of MEM, supplemented with 10% FBS,
1% antibiotic-antimycotic solution, and 1% NEAA at +37°C
± 1 for 24 h, by continuous agitation. An amount of 0.2 g of
each filler was dissolved in 1ml of extraction medium. The
extraction medium without sample was used as reagent con-
trol (RC) and treated as a sample. A 5% phenol solution was
used as positive control (PC).
2.4. Cytotoxicity Test on the L929 Cell Line. Cells were seeded
into 96-well culture plates at 1 × 105 cells/ml ratio in MEM,
supplemented with 10% FBS, 1% antibiotic-antimycotic solu-
tion, and 1% NEAA. Three 96-well culture plates for each
filler were prepared and incubated at +37°C ± 1 in 5% CO2
for 24 h. After this time, culture media were replaced with
100μl of each filler extract and the control extracts and
a series of twofold dilutions (from 100% to 3,125% con-
centrations). The assay was carried out in triplicate. More-
over, intralaboratory assays were performed. Some wells
were filled with MEM, supplemented with 10% FBS, 1%
antibiotic-antimycotic solution, and 1% NEAA, and used as
control cells (negative control). All plates were incubated at
+37 ± 1°C in a 5% CO2 atmosphere and examined micro-
scopically after 24 h, 48 h, and 72h of incubation in order
to assess vitality and general morphology of cells. The vitality
MTS assay was performed at the same time points as previ-
ously described [12]. The absorbance recorded is directly
proportional to the number of living cells. All samples and
controls were compared with negative control to calculate
the percentage of vital cells, using the following equation:
Viab% = 100 × O:D490eO:D490b
, ð1Þ
where O.D490e is the mean value of the measured optical den-
sity of extracts and O.D490b is the mean value of the measured
optical density of the negative control. A sample is consid-
ered cytotoxic if the percentage vitality value is <70% and
noncytotoxic if the percentage vitality value is >70%.
2.5. Proliferation Test on the L929 Cell Line. Cells were seeded
into ten 12.5 cm2 cell culture flasks at 4 × 104 cells/ml in a
total volume of 5ml of extraction medium containing sample
(0.2 g/ml). One flask containing only extraction medium was
used as control (RC). Cells were maintained at +37°C ± 1 in a
humidified 5% CO2 atmosphere and monitored daily by
using an inverted microscope for 72 h. After 72h of incuba-
tion, cells were trypsinized and counted by using a Burker
camera and Trypan blue staining, in order to evaluate the
proliferation rate.
2.6. Haematoxylin/Eosin Staining on the L929 Cell Line. Cells
were seeded into 6-well culture plates at 1 × 105 cells/ml ratio
in extractionmedium containing each sample. Cells were main-
tained at +37°C ± 1 in a humidified 5% CO2 atmosphere for
72h in order to perform haematoxylin/eosin staining. Briefly,
media were removed from each well and cells were washed with
PBS and fixed in methanol; 1% haematoxylin (Sigma-Aldrich)
solution was added, followed by PBS washings and 1% eosin
staining (Sigma-Aldrich). Cell morphology was evaluated by
using an inverted microscope supplied with a camera (Leica).
3. Results
Figure 1 shows results the calculation using the equation (1)

























































Figure 1: Effects of HA filler extracts and controls on L929 cells at 24 h, 48 h, and 72 h of exposure. Data express the percentage of cell
viability.













the different extracts. The results of cell viability showed that
none of the nine fillers analysed had cytotoxic effects on L929
cells at 24 h, 48 h, and 72 h, having viability values > 70%.
However, filler 2 and filler 6 showed a higher cell viability
percentage in comparison to other fillers tested and to the
RC at 72 h, while filler 1 showed the lowest cell viability per-
centage at 72 h. Phenol solution 0.5% induced high levels of
mortality (viability < 9%). Diluted samples induced no cyto-
toxicity; diluted phenol solution induced cytotoxicity until
the 0.125% concentration (data not shown).
Data obtained from the cell proliferation test are reported
in Table 2. Filler 1 and filler 4 showed a lower cell number
after 72 h grown; filler 2 and filler 6 showed an overgrowth
of cells suggesting a proliferative effect of these samples on
cells; the other samples showed a cell proliferation rate com-
parable to RC. Figure 2 shows the morphology of L929 when
cultured with filler 1 (low cell count), filler 2 (high cell count),
filler 4 (low cell count), filler 5 (cell count similar to RC), filler
6 (high cell count), and RC for 24 h, 48 h, and 72 h. The last
column shows cells stained with haematoxylin/eosin at
72 h. The other samples (fillers 3, 7, 8, and 9) showed a mor-
phology and cell growth similar to RC (data not shown).
Moreover, no micorbic growth was observed during the
monitoring of cell cultures in contact with the fillers.
4. Discussion
In this work, authors report an in vitro study conducted on
nine HA dermal fillers among the most commonly used in
aesthetic medicine and dermatology, randomly received in
the laboratory. According to the UNI EN ISO 10993 regula-
tion, the L929 cell line was chosen for cytotoxicity assay, cell
proliferation test, and cell morphology evaluation by haema-
toxylin/eosin staining. As demonstrated in a previous study,
L929 cells are suitable to undergo a cytotoxicity test by
MTS assay, as they are sensible to the reference materials
indicated in the rule and able to well respond against any










Figure 2: Morphologic evaluation of L929 cells exposed to different HA filler extracts. Observation conduced at 24 h (first column), 48 h
(second column), 72 h (third column), and haematoxylin/eosin staining after 72 h (forth column). Magnification 100x.
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MTS assay was chosen due to its low cost, accuracy, rapidity,
and reproducibility. In addition, cells were cultured with
fillers to evaluate the effects on cell growth in terms of cell
count and morphology. These are two simple and rapid
methods that, together with MTS assay, could improve the
assessment of the biocompatibility of a material designed
for human use [18].
Although all samples tested did not shown any cytotoxic
effect on L929 cells (cell viability > 70%) after 24 h, 48 h, and
72 h, two of tested samples (fillers 2 and 6) showed a higher
cell viability percentage compared to RC while other two
samples (fillers 1 and 4) showed a lower percentage of viabil-
ity compared to the same control (Figure 1). Moreover, the
samples showed different effects on morphology of cell
monolayers and on cell count. After 72h of exposition of
L929 to fillers, cell count was comparable to the untreated
control (RC) for most of the samples, while fillers 1 and 4
showed a cell count reduced by about half and fillers 2 and
6 showed a significant increase in cell count. These results
show that, although all examined fillers are not cytotoxic,
some of them could have a different in vitro behaviour on cell
proliferation by promoting or inhibiting it. These observa-
tions were confirmed during the daily monitoring of the
monolayers by an optical microscope, since they reached
the confluence in different times. Although data on the
in vivo effect are not considered in this study, this different
behaviour could lead to some in vivo implications in terms
of effectiveness of treatment.
In recent years, the use of HA dermal fillers has widely
spread in aesthetic medicine and dermatology [6, 19]. HA
is a natural and biocompatible polymer that has a rapid turn-
over and is quickly degraded by enzymes. To produce a more
resistant form of HA, it is cross-linked and stabilized using
other substances. According to the cross-linking techniques,
HA fillers are classified in monophasic or biphasic [20–22].
Results presented in this study demonstrate that the augment
or decrease of the cell number does not depend on the nature
of the filler (monophasic or biphasic). Injectable fillers are
considered medical devices for which a control by the com-
petent authorities is not required. However, it could be advis-
able to investigate about their in vitro effects in order to
support their safety and to guarantee the absence of risks
for the customer. According to the European Directive
63/2010/EU, standardized and validated in vitro methods
could significantly contribute to limit the use of laboratory
animals in biocompatibility tests. Therefore, in that contest,
this study shows the suitability of some easy and rapid cell-
based methods to assess the biocompatibility and the
in vitro effects of HA fillers largely used in aesthetic medicine
and dermatology and also predicts a possible in vivo effects in
terms of safety and efficacy.
5. Conclusions
All HA fillers tested did not shown any cytotoxic effect on
L929 cells (cell viability > 70%) after 24 h, 48 h, and 72h.
Two samples showed a higher cell viability percentage and
two samples showed a lower percentage compared to RC.
Differences were also found on morphology of cell mono-
layers and on cell count. These results show that, although
all examined fillers are not cytotoxic, some of them could
have different effects on cell proliferation and grown. The
easy and rapid assays performed could be useful to test new
materials, in terms of cytotoxicity and effects on cells,
intended for human use without animal tests.
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